Long-Term Immunogenicity after One and Two Doses of a Monovalent MF59-Adjuvanted A/H1N1 Influenza Virus Vaccine Coadministered with the Seasonal 2009-2010 Nonadjuvanted Influenza Virus Vaccine in HIV-Infected Children, Adolescents, and Young Adults in a Randomized Controlled Trial

Short Communication: Immunogenicity of an Inactivated Influenza Vaccine and Postvaccination Influenza Surveillance in HIV-Infected and Noninfected Children and Adolescents

(2011) Alessandra Aparecida Machado et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age

(2011) Adriano Arguedas et al.   Human vaccines & immunotherapeutics

Response to 2009 Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Patients and the Influence of Prior Seasonal Influenza Vaccination

(2011) Darius Soonawala et al.   PLoS One

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

(2011) Susanna Esposito et al.   VACCINE

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

(2011) Nancy F. Crum-Cianflone et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

Pandemic influenza vaccine in adult HIV-1-infected patients

(2010) Giovanna Orlando et al.   AIDS

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

(2010) Pablo Tebas et al.   AIDS

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1-Infected Patients

(2010) M. Bickel et al.   CLINICAL INFECTIOUS DISEASES

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Do children infected with HIV receiving HAART need to be revaccinated?

(2010) Catherine G Sutcliffe et al.   LANCET INFECTIOUS DISEASES

Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy

(2010) Alberto Cagigi et al.   LANCET INFECTIOUS DISEASES

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Influenza surveillance in a cohort of HIV-infected children and adolescents immunized against seasonal influenza

(2010) Antonella Amendola et al.   VACCINE

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses

(2009) Ken M Kunisaki et al.   LANCET INFECTIOUS DISEASES

Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans

(2009)   NEW ENGLAND JOURNAL OF MEDICINE